Article
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
The Journal of infectious diseases - 1 Jan 1999
Schapiro J M, Lawrence J, Speck R, Winters M A, Efron B, Coombs R W, Collier A C, Merigan T C
Abstract excerpt
The relationships among treatment regimens, plasma human immunodeficiency virus (HIV) RNA levels, and resistance mutations to saquinavir (codons 48 and 90) and zidovudine (codon 215) were examined in a cohort of 144 patients from the AIDS Clinical Trials Group 229 study. After 24-40 weeks of therapy, no patients who had received the two-drug combination (zidovudine plus saquinavir) had only codon 48 mutations,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
